1.            Sweetat, S. et al. Ovariectomy and High Fat-Sugar-Salt Diet Induced Alzheimer’s Disease/Vascular Dementia Features in Mice. Aging Dis. 15, 2284–2300 (2024).

2.            Mishra, K. et al. The Autophagic Activator GHF-201 Can Alleviate Pathology in a Mouse Model and in Patient Fibroblasts of Type III Glycogenosis. Biomolecules 14, (2024).

3.            Appel, S. et al. Sensory disturbances in Creutzfeldt-Jakob disease. Neurol. Sci. 45, 1057–1062 (2024).

4.            Farfara, D. et al. Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice. J. Neuroinflammation 20, (2023).

5.            Balash, Y. et al. Is There Horizontal Transmission of Creutzfeldt-Jakob Disease? Neuroepidemiology 57, 156–161 (2023).

6.            Sweetat, S. et al. The Beneficial Effect of Mitochondrial Transfer Therapy in 5XFAD Mice via Liver–Serum–Brain Response. Cells 12, (2023).

7.            Safadi, D. et al. The epidemiological and clinical characteristics of patients with young-onset genetic Creutzfeldt-Jakob disease. Neurol. Res. 45, 854–857 (2023).

8.            Menendez, L. et al. Genetic Creutzfeldt-Jakob disease in Turkish Jews—demographic and clinical features. Acta Neurol. Scand. 146, 586–589 (2022).

9.            Samuel, I. et al. Sleeve Gastrectomy Reduces Glycemia but Does Not Affect Cognitive Impairment in Lean 5xFAD Mice. Front. Neurosci. 16, (2022).

10.          Trachtenbroit, I. et al. Epidemiological and clinical characteristics of patients with late-onset Creutzfeldt-Jakob disease. Neurol. Sci. 43, 4275–4279 (2022).

11.          Kakhlon, O. et al. Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism. EMBO Mol. Med. 13, (2021).

12.          Appel, S. et al. Spatial distribution of abnormal EEG activity in Creutzfeldt-Jakob disease. Neurophysiol. Clin. 51, 219–224 (2021).

13.          Binyamin, O. et al. Author Correction: Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice (Scientific Reports, (2019), 9, 1, (18437), 10.1038/s41598-019-54971-9). Sci. Rep. 10, (2020).

14.          Nitsan, Z. et al. Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course. J. Neurol. 267, 2455–2458 (2020).

15.          Cohen, O. S. et al. Pseudo-anticipation in Creutzfeldt–Jakob disease is due to a rhomboid-shaped artifact. Eur. J. Neurol. 27, 596–602 (2020).

16.          Lahiani-Cohen, I., Touloumi, O., Lagoudaki, R., Grigoriadis, N. & Rosenmann, H. Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice. Front. Cell Dev. Biol. 7, (2020).

17.          Benhamron, S. et al. Cerebrospinal Fluid (CSF) Exchange Therapy with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Cognitive Deficits and Brain Pathology in Alzheimer’s Disease Mice. J. Alzheimer’s Dis. 76, 369–385 (2020).

18.          Binyamin, O. et al. Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice. Sci. Rep. 9, (2019).

19.          Appel, S. et al. The association of quantitative EEG and MRI in Creutzfeldt-Jakob Disease. Acta Neurol. Scand. 140, 366–371 (2019).

20.          Cohen, O. S. et al. Disease duration in E200K familial Creutzfeldt–Jakob disease is correlated with clinical, radiological, and laboratory variables. J. Neural Transm. 126, 607–611 (2019).

21.          Valitsky, M. et al. Cerebrospinal fluid (CSF) exchange with artificial csf enriched with mesenchymal stem cell secretions ameliorates experimental autoimmune encephalomyelitis. Int. J. Mol. Sci. 20, (2019).

22.          Nitzan, K. et al. Mitochondrial Transfer Ameliorates Cognitive Deficits, Neuronal Loss, and Gliosis in Alzheimer’s Disease Mice. J. Alzheimers. Dis. 72, 587–604 (2019).

23.          Benhamron, S., Rozenstein-Tsalkovich, L., Nitzan, K., Abramsky, O. & Rosenmann, H. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques. Exp. Neurol. 303, 48–58 (2018).

24.          Cohen, O. S. et al. Clinical radiological correlation in E200K familial Creutzfeldt–Jakob disease. J. Neural Transm. 123, 1457–1462 (2016).

25.          Cohen, O. S. et al. CSF tau correlates with the degree of cortical involvement in E200K familial Creutzfeldt-Jakob disease. Neurosci. Lett. 634, 76–78 (2016).

26.          Cohen, O. S. et al. Unusual presentations in patients with E200K familial Creutzfeldt-Jakob disease. Eur. J. Neurol. 23, 871–877 (2016).

27.          Cohen, O. S. et al. CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol. Scand. 133, 119–123 (2016).

28.          Hellmann, M. A. et al. Frequent misdiagnosis of adult polyglucosan body disease. J. Neurol. 262, 2346–2351 (2015).

29.          Orhan Akman, H. et al. Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease. JAMA Neurol. 72, 441–445 (2015).

30.          Cohen, O. S. et al. Familial Creutzfeldt–Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. J. Neurol. 262, 604–613 (2015).

31.          Appel, S. et al. Seizures in E200K familial and sporadic Creutzfeldt-Jakob disease. Acta Neurol. Scand. 131, 152–157 (2015).

32.          Cohen, O. S. et al. Characterization of sleep disorders in patients with E200K familial Creutzfeldt–Jakob disease. J. Neurol. 262, 443–450 (2015).

33.          Mattsson, N. et al. Erratum: CSF biomarker variability in the Alzheimer’s Association quality control program (Alzheimer’s and Dementia (2013) 9 (251-261)). Alzheimer’s Dement. 11, 237 (2015).

34.          Gotkine, M. et al. Erratum: Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice (BioMed Research International). Biomed Res. Int. 2015, (2015).

35.          Jiang, T., Chang, R. C.-C., Rosenmann, H. & Yu, J.-T. Advances in Alzheimer’s disease: From bench to bedside. Biomed Res. Int. 2015, (2015).

36.          Rosenmann, H. Asparagine endopeptidase cleaves tau and promotes neurodegeneration. Nat. Med. 20, 1236–1238 (2014).

37.          Rozenstein-Tsalkovich, L. et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 248, 451–456 (2013).

38.          Boimel, M. et al. Corrigendum to ‘Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice’ [Exp. Neurol. 224/2 (2010) 472-485]. Exp. Neurol. 247, 8 (2013).

39.          Rosenmann, H. Immunotherapy for targeting tau pathology in Alzheimer’s disease and tauopathies. Curr. Alzheimer Res. 10, 217–228 (2013).

40.          Mattsson, N. et al. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimer’s Dement. 9, 251–261 (2013).

41.          Marc, G. et al. Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice. Biomed Res. Int. 2013, (2013).

42.          Rosenmann, H. & Meiner, Z. [Frontotemporal dementia: clinical features, genetics, pathogenesis and treatment]. Harefuah 152, 661-666,687 (2013).

43.          Lee, H. et al. Cerebral white matter disruption in Creutzfeldt-Jakob disease. Am. J. Neuroradiol. 33, 1945–1950 (2012).

44.          Rosenmann, H., Blum, D., Kayed, R. & Ittner, L. M. Tau protein: Function and pathology. Int. J. Alzheimers. Dis. (2012) doi:10.1155/2012/707482.

45.          Mochel, F. et al. Adult polyglucosan body disease: Natural history and key magnetic resonance imaging findings. Ann. Neurol. 72, 433–441 (2012).

46.          Rosenmann, H. CSF biomarkers for amyloid and tau pathology in Alzheimer’s disease. J. Mol. Neurosci. 47, 1–14 (2012).

47.          Cohen, O. S. et al. Characterization of movement disorders in patients with familial creutzfeldt-jakob disease carrying the E200K mutation. Isr. Med. Assoc. J. 14, 162–165 (2012).

48.          Meiner, Z. & Rosenmann, H. [Biological markers in the diagnosis of dementia and Alzheimer’s disease]. Harefuah 151, 289-293,318 (2012).

49.          Cohen, O. S. et al. The Creutzfeldt-Jakob disease (CJD) neurological status scale: A new tool for evaluation of disease severity and progression. Acta Neurol. Scand. 124, 368–374 (2011).

50.          Lahiani-Cohen, I. et al. Moderate environmental enrichment mitigates tauopathy in a neurofibrillary tangle mouse model. J. Neuropathol. Exp. Neurol. 70, 610–621 (2011).

51.          Ginsburg, I., Rozenstein-Tsalkovich, L., Koren, E. & Rosenmann, H. The herbal preparation padma® 28 protects against neurotoxicity in PC12 cells. Phyther. Res. 25, 740–743 (2011).

52.          Meiner, Z. et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J. Neurol. 258, 255–262 (2011).

53.          Cohen, O. S. et al. Pruritus in familial Creutzfeldt-Jakob disease: A common symptom associated with central nervous system pathology. J. Neurol. 258, 89–95 (2011).

54.          Boimel, M. et al. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472–485 (2010).

55.          Inbar, D., Belinson, H., Rosenman, H. & Michaelson, D. M. Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade. Neurodegener. Dis. 7, 16–23 (2010).

56.          Appel, S. A. et al. Rapidly progressive Creutzfeldt-Jakob disease in patients with Familial Mediterranean Fever. Eur. J. Neurol. 17, 861–865 (2010).

57.          Shiryaev, N. et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol. Dis. 34, 381–388 (2009).

58.          Boimel, M. et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68, 314–325 (2009).

59.          Lee, H. et al. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain 132, 2680–2687 (2009).

60.          Dresner-Pollak, R. et al. Estrogen receptor beta gene variant is associated with vascular dementia in elderly women. Genet. Test. Mol. Biomarkers 13, 339–342 (2009).

61.          Rosenmann, H. et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 212, 71–84 (2008).

62.          Rosenmann, H., Meiner, Z., Geylis, V., Abramsky, O. & Steinitz, M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects. Neurosci. Lett. 410, 90–93 (2006).

63.          Rosenmann, H. et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63, 1459–1467 (2006).

64.          Meiner, V. et al. Preimplantation exclusion of embryos at risk for prion diseases. Neurology 66, 607–608 (2006).

65.          Lossos, A. et al. Phenotypic variability among adult siblings with Sjögren-Larsson syndrome. Arch. Neurol. 63, 278–280 (2006).

66.          Meiner, Z., Newman, J. P., Rosenman, H., Soffer, D. & Steiner, I. Frontotemporal dementia with ubiquitinated neuronal inclusions and visuospatial impairment. Neurology 65, 478–480 (2005).

67.          Lossos, A. et al. Extended phenotype in the transthyretin Tyr77 familial amyloid polyneuropathy. Eur. Neurol. 53, 55–59 (2005).

68.          Rosenmann, H. et al. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer’s disease. Am. J. Med. Genet. - Neuropsychiatr. Genet. 128 B, 123–125 (2004).

69.          Rosenmann, H. et al. Lack of association of interleukin-1beta polymorphism with Alzheimer’s disease in the Jewish population. Neurosci. Lett. 363, 131–133 (2004).

70.          Rosenmann, H. et al. The fas promoter polymorphism at position -670 is not associated with late-onset sporadic Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 17, 143–146 (2004).

71.          Hijazi, N., Shaked, Y., Rosenmann, H., Ben-Hur, T. & Gabizon, R. Copper binding to PrPC may inhibit prion disease propagation. Brain Res. 993, 192–200 (2003).

72.          Lossos, A. et al. Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family. J. Neurol. 250, 733–740 (2003).

73.          Rosenmann, H. et al. An association study of the codon 72 polymorphism in the pro-apoptotic gene p53 and Alzheimer’s disease. Neurosci. Lett. 340, 29–32 (2003).

74.          Rosenmann, H. et al. A polymorphism in the complement component C1r is not associated with sporadic Alzheimer’s disease. Neurosci. Lett. 336, 101–104 (2003).

75.          Shaked, G. M., Engelstein, R., Avraham, I., Rosenmann, H. & Gabizon, R. Valproic acid treatment results in increased accumulation of prion proteins. Ann. Neurol. 52, 416–420 (2002).

76.          Shaked, Y., Rosenmann, H., Hijazi, N., Halimi, M. & Gabizon, R. Copper binding to the PrP isoforms: A putative marker of their conformation and function. J. Virol. 75, 7872–7874 (2001).

77.          Rosenmann, H. et al. Prion protein with an E200K mutation displays properties similar to those of the cellular isoform PrPC. J. Neurochem. 76, 1654–1662 (2001).

78.          McNally, E. M. et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am. J. Med. Genet. 91, 305–312 (2000).

79.          Simon, E. S. et al. Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200k mutation. Ann. Neurol. 47, 257–260 (2000).

80.          Argov, Z. et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 123, 1229–1237 (2000).

81.          Shaked, Y., Rosenmann, H., Talmor, G. & Gabizon, R. A C-terminal-truncated PrP isoform is present in mature sperm. J. Biol. Chem. 274, 32153–32158 (1999).

82.          Rosenmann, H. et al. Preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease. Neurology 53, 1328–1329 (1999).

83.          Rosenmann, H., Vardi, J., Finkelstein, Y., Chapman, J. & Gabizon, R. Identification in Israel of 2 Jewish Creutzfeldt-Jakob disease patients with a 178 mutation at their PrP gene. Acta Neurol. Scand. 97, 184–187 (1998).

84.          Rosenmann, H., Halimi, M., Kahana, I., Biran, I. & Gabizon, R. Differential allelic expression of PrP mRNA in carriers of the E200K mutation. Neurology 49, 851–856 (1997).

85.          Rosenmann, H. et al. Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt Jakob disease. Neurology 49, 593–595 (1997).

86.          Ovadia, H. et al. Effect of scrapie infection on the activity of neuronal nitric-oxide synthase in brain and neuroblastoma cells. J. Biol. Chem. 271, 16856–16861 (1996).

87.          Spudich, S. et al. Complete penetrance of Cruetzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol. Med. 1, 607–613 (1995).

88.          Gabizon, R. et al. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am. J. Hum. Genet. 53, 828–835 (1993).